Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide in Lennox-Gastaut Syndrome
NCT01146951Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2010
- Primary completion
- Aug 2011
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Rufinamide with Placebo (2 arms). Primary endpoint: Percent Change in Tonic-Atonic Seizure Frequency From Baseline at 28 days. Started Jun 2010; status: completed.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT01146951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146951.